The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...
Labeling would drop the limitation of use for age-related hypogonadism, reflecting an evidence reassessment that no longer supports language implying unestablished safety and effectiveness in this ...
The application is supported by data from the phase 3 LITESPARK-022 trial. The FDA has approved belzutifan (Welireg) in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase ...
The approval is supported by data from the phase 3 PIVOT-PO trial, in which tebipenem demonstrated noninferiority to imipenem-cilastatin. This decision marks the first approval of an oral carbapenem ...
The approval is supported by data from the phase 3 CAPItello-281 trial. On June 12, 2026, the FDA approved capivasertib (Truqap) in combination with abiraterone acetate (Zytiga) and prednisone for ...
Live Events | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results